Table 3.
Anthropometric features, blood pressure and blood parameters in participants with and without NAFLD, according to Ultrasound (Hamaguchi score ≥ 4) expressed as median (interquartile range).
| Variable | Overall sample (n = 60) | Females (n = 30) | Males (n = 30) | |||
|---|---|---|---|---|---|---|
| NAFLD (−) (n = 34) | NAFLD (+) (n = 26) | NAFLD (−) (n = 18) | NAFLD (+) (n = 12) | NAFLD (−) (n = 16) | NAFLD (+) (n = 14) | |
| Body-Mass Index (kg/m2) | 24.5 | 30.8 ** | 24.9 | 29.5 ‡ | 24 | 31.6 ** |
| (22.2–28.2) | (26.7–34.5) | (22.6–28.2) | (24.6–35.5) | (22–28) | (27.9–33.9) | |
| Waist circumference (cm) | 77.7 | 93.6 ** | 75.6 | 85.8 ‡ | 79.0 | 96.6 ** |
| (73.4–85.0) | (83.9–102.4) | (71.4–85.0) | (75.0–99.4) | (74.2–85.5) | (90.7–102.4) | |
| Systolic Blood Pressure (mm Hg) | 108.4 | 120.9 ** | 109.4 | 114.4 | 106.9 | 124.5 ** |
| (105–119) | (110–130) | (104.3–117) | (103–127) | (105–120.7) | (120–130) | |
| Diastolic Blood Pressure (mm Hg) | 68.4 | 78.5 ** | 65.4 | 66.7 | 69.3 | 80 ** |
| (63.3–70) | (68.3–80.7) | (64–70) | (61.2–82.2) | (60.8–76.3) | (78.3–80.7) | |
| Blood glucose (mg/dL) | 90.7 | 91 | 89.3 | 88.2 | 91.5 | 92.9 |
| (83.5–93.3) | (88–94.4) | (83.4–92.8) | (82.9–93) | (86.7–94.6) | (90–96.4) | |
| Fasting insulin (uUI/dL) | 12.1 | 19.8 ** | 13.4 | 17.5 | 11.3 | 21.8 ** |
| (8.8–16.3) | (11–38.6) | (10.1–18) | (10–45.5) | (8.6–14.2) | (13.1–38.6) | |
| HOMA-IR (arbitrary units) | 2.7 | 4.5 ** | 2.9 | 4 | 2.6 | 4.8 ** |
| (2–3.5) | (2.1–7.3) | (1.9–3.8) | (2.1–6.4) | (2–3.1) | (3.1–8.4) | |
| Total Cholesterol (mg/dL) | 158 | 165 | 164 | 166 | 149 | 166 |
| (130–184) | (138–196) | (130–187) | (138–202) | (127–176) | (138–191) | |
| High- density lipoprotein cholesterol (mg/dL) | 42.5 | 39.0 | 46.1 | 43.5 | 38.3 | 35.9 |
| (32.4–49.8) | (32.1–44.5) | (34.8–51) | (36–47.9) | (30.2–45.5) | (29.3–39.5) | |
| Triglycerides (mg/dL) | 78.5 | 105.5 ‡ | 86.7 | 85.6 | 64 | 135.3 ‡ |
| (60.2–105.2) | (56.3–182.6) | (65.9–105.2) | (51.3–129.7) | (56.5–109.6) | (66.4–196.8) | |
| High-sensitivity C-reactive protein (mg/L) (n = 57) | 1.57 | 1.70 | 1.87 | 2.02 | 1.29 | 1.61 |
| (1.1–2.7) | (1.2–3.3) | (1.2–2.4) | (1.2–3.3) | (1.1–2.8) | (1.2–6.0) | |
| Adiponectin (µg/mL) | 6.54 | 4.49 | 7.47 | 7.05 | 9.27 | 3.71 |
| (2.6–10.5) | (3.2–8.8) | (3.8 -8.8) | (2.6–8.69) | (2.6–9.27) | (1.7–5.5) | |
| Alanine transaminase (IU/L) | 29.5 | 38.0 ** | 31.3 | 32.7 | 28.4 | 58.3 ** |
| (25–36.5) | (31.5–66) | (26.1–36.5) | (24.9–38) | (23.9–38.3) | (32.9–88.8) | |
| Aspartate transaminase (IU/L) | 37.2 | 38.5 | 37.2 | 37.2 | 39.3 | 45.4 |
| (27.5–43.5) | (30.9–50.5) | (31.3–42.6) | (31.6–40.1) | (27–46.5) | (27.7–61.7) | |
Wilcoxson rank-sum test comparing participants with (+) and without (−) NAFLD. ** Significant at α of 0.01. ‡ Trend towards significance. Participants with high-sensitivity C-reactive protein values >9 mg/L were excluded from the analysis (n = 3).